• FDA Approves Brigatinib for ALK-Positive Metastatic NSCLC americanpharmaceuticalreview
    June 02, 2020
    The Food and Drug Administration (FDA) approved brigatinib (ALUNBRIG, ARIAD) for adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
PharmaSources Customer Service